CFO4Life Group LLC Invests $217,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

CFO4Life Group LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 416 shares of the medical equipment provider’s stock, valued at approximately $217,000.

A number of other hedge funds have also made changes to their positions in ISRG. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical during the 4th quarter worth about $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $31,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Intuitive Surgical during the 3rd quarter valued at $33,000. Finally, Decker Retirement Planning Inc. purchased a new position in Intuitive Surgical in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Brian Edward Miller sold 8,900 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the transaction, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at approximately $2,793,033.06. This represents a 60.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jamie Samath sold 94 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total value of $53,684.34. Following the completion of the sale, the chief financial officer now directly owns 2,630 shares in the company, valued at approximately $1,502,019.30. This represents a 3.45 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,209 shares of company stock worth $11,928,127. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Down 4.1 %

ISRG stock opened at $476.78 on Friday. The company has a market cap of $169.82 billion, a P/E ratio of 74.38, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The business’s fifty day moving average is $568.47 and its 200-day moving average is $531.22. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00.

Wall Street Analyst Weigh In

ISRG has been the topic of several analyst reports. Citigroup increased their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. BTIG Research upped their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Barclays increased their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Bernstein Bank lifted their price target on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, Truist Financial upped their price objective on Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.